Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 12/20 | 0.50 |
| ▸ | AKT2 | P31751 | 11/20 | 0.50 |
| ▸ | AKT3 | Q9Y243 | 11/20 | 0.50 |
| ▸ | AKT1S1 | Q96B36 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13229989 | 0.85 | AKT1 (0.59) | AKT1AKT2AKT3AKT1S1RAB9A | |
| Hydrochloric Acid SCHEMBL2798901 | 0.85 | AKT1 (0.58) | AKT1AKT2AKT3AKT1S1RAB9A | |
| Hydrochloric Acid SCHEMBL6017516 | 0.83 | AKT1 (0.56) | AKT1AKT2AKT3AKT1S1RAB9A | |
| SCHEMBL2797874 | 0.80 | AKT1 (0.61) | AKT1AKT2AKT3AKT1S1 | |
| SCHEMBL2800148 | 0.80 | AKT1 (0.61) | AKT1AKT2AKT3AKT1S1 | |
| SCHEMBL2797242 | 0.76 | AKT1 (0.55) | AKT1AKT2AKT3AKT1S1KIT | |
| SCHEMBL2800686 | 0.74 | AKT1 (0.62) | AKT1AKT2AKT3AKT1S1PDGFRB | |
| SCHEMBL2797356 | 0.73 | MALT1 (0.44) | AKT1AKT2AKT3AKT1S1PDGFRB | |
| SCHEMBL12215173 | 0.73 | KIT (0.64) | AKT1AKT2AKT3AKT1S1PDGFRB | |
| SCHEMBL2797481 | 0.73 | AKT1 (0.57) | AKT1AKT2AKT3AKT1S1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8680114-B2 | AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2010-07-01 | — | — | US | disclosed |
| EP-1684694-A2 | AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005051304-A2 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | AKT1 1/4885AKT2 2/4885AKT3 3/4885 |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | AKT1 1/4885AKT2 2/4885AKT3 3/4885 |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | AKT1 1/4885AKT2 2/4885AKT3 3/4885 |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | MTOR, CDK2, CLK2 | AKT1 25/4885AKT2 71/4885AKT3 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.